Celldex Stock Plunges as Urticaria Drug Efficacy Falls Short of High Expectations

Shares of Celldex Therapeutics (NASDAQ: CLDX) plunged on Tuesday, falling 10.4% in midday trading despite the company announcing positive results from two Phase 3 trials for its chronic spontaneous urticaria (CSU) treatment. The sharp intraday reversal reflected a classic "sell the news" event, as investors weighed the clinically successful, yet commercially underwhelming, efficacy data against elevated expectations.

Trial Meets Endpoints, Disappoints on Magnitude

The two Phase 3 studies, EMBARQ-CSU1 and EMBARQ-CSU2, successfully met their primary endpoint, showing a statistically significant mean change in the urticaria activity score (UAS7) at Week 12. The trials, which enrolled 1,939 patients, also met all key secondary endpoints.

However, the source of investor disappointment appears to be the magnitude of the drug's effect. The data showed a placebo-adjusted improvement of approximately 10 points on the UAS7 scale. While clinically meaningful, this represented a step down from the roughly 13-point improvement observed in the drug's Phase 2 trial, a gap that seemingly failed to meet the market's high bar for a best-in-class profile.

Analyst View and Market Context

Ad

Despite the market's negative reaction, some analysts maintained a constructive view on the drug's future. Stifel reiterated its Buy rating and $68 price target, while H.C. Wainwright raised its target to $64 from a previous $42. Celldex plans to submit a Biologics License Application (BLA) to the FDA in 2027.

The sell-off was specific to Celldex, occurring while the broader market was relatively stable, with the S&P 500 flat and the NASDAQ Composite up slightly. This underscores that the stock's decline was driven entirely by the trial data readout and not by wider market sentiment.

Competitive Landscape

The chronic spontaneous urticaria market is competitive, with established treatments like Xolair from Novartis and Roche. For a new entrant like barzolvolimab to capture significant market share, investors were likely looking for efficacy data that demonstrated clear superiority over existing and pipeline therapies. The lower-than-expected improvement in Phase 3 likely raised questions about the drug's ultimate commercial differentiation and potential.